Penumbra (NYSE PEN - Get Rating), had its target price raised by Truist Financial stock analysts from $228.00 – $255.00 in a research document issued Tuesday, Benzinga Reports. The stock currently has a buy rating from the brokerage. Truist Financial's target stock price would indicate an upside potential of 15.84% over the stock's current price.
PEN has been the topic of a variety of reports. StockNews.com reduced Penumbra's rating from a "hold", to a "sell," rating in a research note published Wednesday, November 23rd. Jefferies Financial Group began coverage on Penumbra shares in a report published on Wednesday, October 12, 2012. They gave the stock a "buy" rating with a $230.00 price target. In a research note, Wells Fargo & Company raised their target price for Penumbra shares from $225.00 - $255.00 and gave Penumbra an "overweight". Deutsche Bank Aktiengesellschaft raised their price target for Penumbra from $163.00 - $202.00 in a research report on Wednesday, October 26th. Royal Bank of Canada raised their price target on Penumbra to $195.00 from $202.00 in a research note on Tuesday, October 26th. The stock has been rated by one research analyst with a sell rating, and 12 analysts have given the stock a buy rating. MarketBeat data shows that Penumbra currently has a rating of "Moderate buy" and a consensus price target at $234.18.
Penumbra Trading Up 0.2 %
NYSE PEN shares traded $0.36 higher during Tuesday's midday trading, reaching $220.13 10,432 shares were traded, compared with its average volume (325,726). Penumbra's 12 month low was $114.86, and its 12 month high was $290.36. Market capitalization is $8.36 billion. The company has a price to earnings ratio of -268.59, and a beta score of 0.51. The company has a debt to equity ratio of 0.03, a current ratio 5.23, and a quick ratio 2.92. The simple moving average for the business is $191.92 over 50 days and $168.15 over two-hundred days.
Penumbra (NYSE PEN - Get Rating), last released its quarterly earnings data Thursday, November 3. The quarter's $0.01 earnings per share was reported by the company, exceeding the consensus estimate ($0.01) by $0.02. Penumbra posted a 0.45% positive return on equity and a negative net loss of 3.68%. For the quarter, revenue was $213.68million, which is lower than the consensus estimate of $212.41million. Equity research analysts predict that Penumbra will report 0.14 EPS in the current year.
Penumbra - Insider Transactions
EVP Johanna Roberts, Penumbra's EVP, sold 1,500 shares in a transaction that took place Monday, November 14. The average price for the shares was $194.48. This transaction totalled $291,720.00. The executive vice president now owns 55.496 shares of stock in the company, which is valued at $10.792,862.08. This hyperlink allows you to access a Securities & Exchange Commission legal filing that disclosed the transaction. In the past 90 days, insiders sold 4,624 shares worth $920.394 of company stock. Corporate insiders control 5.50%.
Hedge Funds Are Interested in Penumbra
Recent transactions have seen institutional investors buy and sell shares in the company. BlackRock Inc. increased its Penumbra stake by 13.1% during the third quarter. BlackRock Inc. now holds 3,904,657 shares in the stock company, which is valued at $740 322,000. The purchase of 453,057 additional shares was made during the quarter. Vanguard Group Inc. increased its Penumbra stake by 2.0% during the third quarter. Vanguard Group Inc. now has 3,407,434 shares in the stock of the company, which is valued at $646.050,000. The purchase of an additional 68.266 shares was made during the quarter. Penumbra's holdings of Price T Rowe Associates Inc. MD increased by 8.0% during the second quarter. After purchasing an additional 90 749 shares during the quarter, Price T Rowe Associates Inc. MD now has 1,231,129 shares in its stock, which is valued at $153,300,000. State Street Corp increased its Penumbra shares by 4.8% in the third quarter. State Street Corp now holds 1,016,516 shares worth $192,731,000. This is after purchasing an additional 46,875 shares during the previous quarter. William Blair Investment Management LLC increased its share of Penumbra shares by 13.3% during the second quarter. William Blair Investment Management LLC now holds 972,675 shares in the company's stock, which is valued at $121,117,000. During the period, it also acquired an additional 113.992 shares. Hedge funds and institutional investors own 81.65%.
Penumbra Company Profile
Penumbra, Inc develops, manufactures, markets, and markets medical products in the United States and abroad. Aspiration-based thrombectomy and accessory systems are offered by the company. These include the Penumbra RED and JET brands. Components and accessories can also be found under the Penumbra SMART Coil 400, PAC400 and PAC400 brands. There are neurovascular access systems that provide intracranial access to a variety of neurovascular therapies, such as Neuron MAX, Select and BENCHMARK brands.
This instant news alert was created using narrative science technology and financial information from MarketBeat to ensure readers receive the most accurate and speediest reporting. MarketBeat's editorial staff reviewed this story before publication. You can send your questions and comments to EMAIL.
This is a must-hear before you think about Penumbra.
MarketBeat tracks Wall Street's top-rated, most successful research analysts. They also track the stocks that they recommend to clients daily. MarketBeat identified five stocks that top analysts whisper to clients to purchase now, before the wider market takes notice... Penumbra was not on the list.
Analysts currently rate Penumbra as a Buy, but top-rated analysts think these five stocks are better investments.
Check Out These Five Stocks